Pharmacovigilance Market (Drug Development: Preclinical Studies, Phase I, Phase II, Phase III, and Phase IV or Post Marketing Surveillance; Type of Methods: Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Mon

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $5,795	151 Pages	Transparency Market Research Pvt. Ltd.	February, 2022	TNPR17067635

Best Price Guarantee
Price	from $5,795
Length	151 Pages
Publisher	Transparency Market Research Pvt. Ltd.
Published Date	February, 2022
SKU	TNPR17067635

Pharmacovigilance Market (Drug Development: Preclinical Studies, Phase I, Phase II, Phase III, and Phase IV or Post Marketing Surveillance; Type of Methods: Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring, and EHR Mining; and Type of Service: In-house and Contract Outsourcing) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2028

Pharmacovigilance Market – Scope of Report
TMR’s report on the global pharmacovigilance market studies past as well as current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2021 to 2028. The report provides revenue of the global pharmacovigilance market for the period 2017–2028, considering 2020 as the base year and 2028 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the global pharmacovigilance market during the forecast period.

The report has been prepared after an extensive primary and secondary research. Primary research involved bulk of research efforts, wherein analysts carried out interviews with industry leaders and opinion makers. Extensive secondary research involved referring to key players’ literature, annual reports, press releases, and relevant documents to understand the global pharmacovigilance market.

Secondary research also included Internet sources, statistical data from government agencies, websites, company presentations, sales data, and trade associations. Analysts have employed a combination of top-down and bottom-up approaches to study various phenomenon in the global pharmacovigilance market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Furthermore, the report sheds light on the changing competitive dynamics in the global pharmacovigilance market. These indices serve as valuable tools for existing market players as well as for entities interested in entering the global pharmacovigilance market.

The report delves into the competition landscape of the global pharmacovigilance market. Key players operating in the global pharmacovigilance market have been identified, and each one of these has been profiled for distinguishing business attributes. Company overview, financial standings, recent developments, and SWOT are some of the attributes of players in the global pharmacovigilance market that have been profiled in this report.

Key Questions Answered in Pharmacovigilance Market Report
What is the scope of growth of phase of drug development companies in the global pharmacovigilance market?
What will be the Y-o-Y growth of the global pharmacovigilance market between 2019 and 2027?
What is the influence of changing trends in technologies on the global pharmacovigilance market?
Which region is likely to be the most profitable market for pharmacovigilance?
Which factors are anticipated to hamper the growth of the global pharmacovigilance market during the forecast period?
Which are the leading companies in the global pharmacovigilance market?
Research Methodology
A unique research methodology has been utilized by TMR to conduct comprehensive research on the growth of the global pharmacovigilance market and arrive at conclusions on its growth prospects. This research methodology is a combination of primary and secondary research, which helps analysts warrant the accuracy and reliability of the drawn conclusions.

Secondary methods referred to by analysts during the production of the global pharmacovigilance market report include statistics from company annual reports, SEC filings, company websites, investor presentations, regulatory databases, government publications, and industry white papers. Analysts have also interviewed senior managers, product portfolio managers, CEOs, VPs, and market intelligence managers, who contributed to the production of TMR’s study on the pharmacovigilance market as primary methods.

These primary and secondary methods have provided exclusive information during interviews, which serves as a validation from the pharmacovigilance market leaders. Access to an extensive internal repository and external proprietary databases enabled this report to address specific details and questions about the global pharmacovigilance market with accuracy. The study also uses the top-down approach to assess the revenue for each segment and the bottom-up approach to counter-validate them. This has helped in reaching TMR’s estimates on future prospects of the global pharmacovigilance market more reliably and accurately.

Companies Mentioned

Accenture plc
Bristol-Myers Squibb
Clinquest Group B.V.
Cognizant
Labcorp Drug Development
F. Hoffmann-La Roche Ltd.
GlaxoSmithKline plc
ICON plc
iGATE Corporation
iMEDGlobal Corporation
Syneos Health
Novartis AG
PAREXEL International Corporation
Pfizer, Inc.
Pharmaceutical Phase of Drug Development, LLC. (PPD)
IQVIA
Sanofi
Synowledge LLC
Wipro Limited

1. Preface: 1.1. Market Definition and Scope; 1.2. Market Segmentation; 1.3. Key Research Objectives; 1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Pharmacovigilance Market
4. Market Overview: 4.1. Introduction; 4.1.1. Market Definition; 4.1.2. Industry Evolution / Developments; 4.2. Overview; 4.3. Market Dynamics; 4.3.1. Drivers; 4.3.2. Restraints; 4.3.3. Opportunities; 4.4. Global Pharmacovigilance Market Analysis and Forecast, 2017–2028; 4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights: 5.1. COVID-19 Impact on the Pharmacovigilance Market; 5.2. Technological Advancements (big data analytics, cloud-based database, automation); 5.3. Drugs Regulatory Framework of Pharmacovigilance Market; 5.4. Pharmacovigilance Market: Value Chain Analysis; 5.5. Pharmacovigilance Market: Porter’s Five Forces Analysis; 5.6. Overview of Drugs Adverse Effects
6. Global Pharmacovigilance Market Analysis and Forecast, by Phase of Drug Development: 6.1. Introduction & Definition; 6.1.1. Key Findings / Developments; 6.2. Global Pharmacovigilance Market Value Forecast, by Phase of Drug Development, 2017–2028; 6.2.1. Preclinical Studies; 6.2.2. Phase I; 6.2.3. Phase II; 6.2.4. Phase III; 6.2.5. Phase IV or Post Marketing Surveillance; 6.3. Global Pharmacovigilance Market Attractiveness Analysis, by Phase of Drug Development, 2021-2028
7. Global Pharmacovigilance Market Analysis and Forecast, by Type of Method: 7.1. Introduction & Definition; 7.1.1. Key Findings / Developments; 7.2. Global Pharmacovigilance Market Value Forecast, by Type of Method, 2017–2027; 7.2.1. Spontaneous Reporting; 7.2.2. Intensified ADR Reporting; 7.2.3. Targeted Spontaneous Reporting; 7.2.4. Cohort Event Monitoring; 7.2.5. EHR Mining; 7.3. Global Pharmacovigilance Market Attractiveness Analysis, by Type of Method,2021-2028
8. Global Pharmacovigilance Market Analysis and Forecast, by Type of Service: 8.1. Introduction & Definition; 8.1.1. Key Findings / Developments; 8.2. Global Pharmacovigilance Market Value Forecast, by Type of Service, 2017–2027; 8.2.1. In-house; 8.2.2. Contract Outsourcing; 8.3. Global Pharmacovigilance Market Attractiveness Analysis, by Type of Service, 2021-2028
9. Global Pharmacovigilance Market Analysis and Forecast, by Region: 9.1. Key Findings; 9.2. Global Pharmacovigilance Market Value Forecast, by Region; 9.2.1. North America; 9.2.2. Europe; 9.2.3. Asia Pacific; 9.2.4. Latin America; 9.2.5. Middle East & Africa; 9.3. North America Pharmacovigilance Market Attractiveness Analysis, by Region, 2021-2028
10. North America Pharmacovigilance Market Analysis and Forecast: 10.1. Introduction; 10.1.1. Key Findings; 10.2. North America Pharmacovigilance Market Value (US$ Mn) Forecast, by Phase of Drug Development, 2017–2027; 10.2.1. Preclinical Studies; 10.2.2. Phase I; 10.2.3. Phase II; 10.2.4. Phase III; 10.2.5. Phase IV or Post Marketing Surveillance; 10.3. North America Pharmacovigilance Market Value (US$ Mn) Forecast, by Type of Method, 2017–2027; 10.3.1. Spontaneous Reporting; 10.3.2. Intensified ADR Reporting; 10.3.3. Targeted Spontaneous Reporting; 10.3.4. Cohort Event Monitoring; 10.3.5. EHR Mining Others; 10.4. North America Pharmacovigilance Market Value (US$ Mn) Forecast, by Type of Service, 2017–2027; 10.4.1. In-house; 10.4.2. Contract Outsourcing; 10.5. North America Pharmacovigilance Market Value (US$ Mn) Forecast, by Country, 2017–2027; 10.5.1. U.S.; 10.5.2. Canada; 10.6. North America Pharmacovigilance Market Attractiveness Analysis, 2021-2028; 10.6.1. By Phase of Drug Development; 10.6.2. By Type of Method; 10.6.3. By Type of Service; 10.6.4. By Country
11. Europe Pharmacovigilance Market Analysis and Forecast: 11.1. Introduction; 11.1.1. Key Findings; 11.2. Europe Pharmacovigilance Market Value (US$ Mn) Forecast, by Phase of Drug Development, 2017–2027; 11.2.1. Preclinical Studies; 11.2.2. Phase I; 11.2.3. Phase II; 11.2.4. Phase III; 11.2.5. Phase IV or Post Marketing Surveillance; 11.3. Europe Pharmacovigilance Market Value (US$ Mn) Forecast, by Type of Method, 2017–2027; 11.3.1. Spontaneous Reporting; 11.3.2. Intensified ADR Reporting; 11.3.3. Targeted Spontaneous Reporting; 11.3.4. Cohort Event Monitoring; 11.3.5. EHR Mining; 11.4. Europe Pharmacovigilance Market Value (US$ Mn) Forecast, by Type of Service, 2017–2027; 11.4.1. In-house; 11.4.2. Contract Outsourcing; 11.5. Europe Pharmacovigilance Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027; 11.5.1. Germany; 11.5.2. U.K.; 11.5.3. France; 11.5.4. Spain; 11.5.5. Italy; 11.5.6. Rest of Europe; 11.6. Europe Pharmacovigilance Market Attractiveness Analysis, 2021-2028; 11.6.1. By Phase of Drug Development; 11.6.2. By Type of Method; 11.6.3. By Type of Service; 11.6.4. By Country/Sub-region
12. Asia Pacific Pharmacovigilance Market Analysis and Forecast: 12.1. Introduction; 12.1.1. Key Findings; 12.2. Asia Pacific Pharmacovigilance Market Value (US$ Mn) Forecast, by Phase of Drug Development, 2017–2027; 12.2.1. Preclinical Studies; 12.2.2. Phase I; 12.2.3. Phase II; 12.2.4. Phase III; 12.2.5. Phase IV or Post Marketing Surveillance; 12.3. Asia Pacific Pharmacovigilance Market Value (US$ Mn) Forecast, by Type of Method, 2017–2027; 12.3.1. Spontaneous Reporting; 12.3.2. Intensified ADR Reporting; 12.3.3. Targeted Spontaneous Reporting; 12.3.4. Cohort Event Monitoring; 12.3.5. EHR Mining; 12.4. Asia Pacific Pharmacovigilance Market Value (US$ Mn) Forecast, by Type of Service, 2017–2027; 12.4.1. In-house; 12.4.2. Contract Outsourcing; 12.5. Asia Pacific Pharmacovigilance Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027; 12.5.1. China; 12.5.2. Japan; 12.5.3. India; 12.5.4. Australia & New Zealand; 12.5.5. Rest of Asia Pacific; 12.6. Asia Pacific Pharmacovigilance Market Attractiveness Analysis, 2021-2028; 12.6.1. By Phase of Drug Development; 12.6.2. By Type of Method; 12.6.3. By Type of Service; 12.6.4. By Country/Sub-region
13. Latin America Pharmacovigilance Market Analysis and Forecast: 13.1. Introduction; 13.1.1. Key Findings; 13.2. Latin America Pharmacovigilance Market Value (US$ Mn) Forecast, by Phase of Drug Development, 2017–2027; 13.2.1. Preclinical Studies; 13.2.2. Phase I; 13.2.3. Phase II; 13.2.4. Phase III; 13.2.5. Phase IV or Post Marketing Surveillance; 13.3. Latin America Pharmacovigilance Market Value (US$ Mn) Forecast, by Type of Method, 2017–2027; 13.3.1. Spontaneous Reporting; 13.3.2. Intensified ADR Reporting; 13.3.3. Targeted Spontaneous Reporting; 13.3.4. Cohort Event Monitoring; 13.3.5. EHR Mining; 13.4. Latin America Pharmacovigilance Market Value (US$ Mn) Forecast, by Type of Service, 2017–2027; 13.4.1. In-house; 13.4.2. Contract Outsourcing; 13.5. Latin America Pharmacovigilance Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027; 13.5.1. Brazil; 13.5.2. Mexico; 13.5.3. Rest of Latin America; 13.6. Latin America Pharmacovigilance Market Attractiveness Analysis, 2021-2028; 13.6.1. By Phase of Drug Development; 13.6.2. By Type of Method; 13.6.3. By Type of Service; 13.6.4. By Country/Sub-region
14. Middle East & Africa Pharmacovigilance Market Analysis and Forecast: 14.1. Introduction; 14.1.1. Key Findings; 14.2. Middle East & Africa Pharmacovigilance Market Value (US$ Mn) Forecast, by Phase of Drug Development, 2017–2027; 14.2.1. Preclinical Studies; 14.2.2. Phase I; 14.2.3. Phase II; 14.2.4. Phase III; 14.2.5. Phase IV or Post Marketing Surveillance; 14.3. Middle East & Africa Pharmacovigilance Market Value (US$ Mn) Forecast, by Type of Method, 2017–2027; 14.3.1. Spontaneous Reporting; 14.3.2. Intensified ADR Reporting; 14.3.3. Targeted Spontaneous Reporting; 14.3.4. Cohort Event Monitoring; 14.3.5. EHR Mining; 14.4. Middle East & Africa Pharmacovigilance Market Value (US$ Mn) Forecast, by Type of Service, 2017–2027; 14.4.1. In-house; 14.4.2. Contract Outsourcing; 14.5. Middle East & Africa Pharmacovigilance Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027; 14.5.1. GCC Countries; 14.5.2. South Africa; 14.5.3. Rest of Middle East & Africa; 14.6. Middle East & Africa Pharmacovigilance Market Attractiveness Analysis, 2021-2028; 14.6.1. By Phase of Drug Development; 14.6.2. By Type of Method; 14.6.3. By Type of Service; 14.6.4. By Country/Sub-region
15. Competition Landscape: 15.1. Market Player - Competition Matrix (by tier and size of companies); 15.2. Market Share / Position Analysis, by Company, 2020; 15.3. Competitive Business Strategies; 15.4. Company Profiles; 15.4.1. Accenture plc; 15.4.1.1. Company Overview (HQ, Business Segments, Employee Strength); 15.4.1.2. Phase of Drug Development Portfolio; 15.4.1.3. Financial Overview; 15.4.1.4. Strategic Overview; 15.4.1.5. SWOT Analysis; 15.4.2. Bristol-Myers Squibb; 15.4.2.1. Company Overview (HQ, Business Segments, Employee Strength); 15.4.2.2. Phase of Drug Development Portfolio; 15.4.2.3. Financial Overview; 15.4.2.4. Strategic Overview; 15.4.2.5. SWOT Analysis; 15.4.3. Clinquest Group B.V.; 15.4.3.1. Company Overview (HQ, Business Segments, Employee Strength); 15.4.3.2. Phase of Drug Development Portfolio; 15.4.3.3. Financial Overview; 15.4.3.4. Strategic Overview; 15.4.3.5. SWOT Analysis; 15.4.4. Cognizant; 15.4.4.1. Company Overview (HQ, Business Segments, Employee Strength); 15.4.4.2. Phase of Drug Development Portfolio; 15.4.4.3. Financial Overview; 15.4.4.4. Strategic Overview; 15.4.4.5. SWOT Analysis; 15.4.5. Labcorp Drug Development; 15.4.5.1. Company Overview (HQ, Business Segments, Employee Strength); 15.4.5.2. Phase of Drug Development Portfolio; 15.4.5.3. Financial Overview; 15.4.5.4. Strategic Overview; 15.4.5.5. SWOT Analysis; 15.4.6. F. Hoffmann-La Roche Ltd.; 15.4.6.1. Company Overview (HQ, Business Segments, Employee Strength); 15.4.6.2. Phase of Drug Development Portfolio; 15.4.6.3. Financial Overview; 15.4.6.4. Strategic Overview; 15.4.6.5. SWOT Analysis; 15.4.7. GlaxoSmithKline plc; 15.4.7.1. Company Overview (HQ, Business Segments, Employee Strength); 15.4.7.2. Phase of Drug Development Portfolio; 15.4.7.3. Financial Overview; 15.4.7.4. Strategic Overview; 15.4.7.5. SWOT Analysis; 15.4.8. ICON plc; 15.4.8.1. Company Overview (HQ, Business Segments, Employee Strength); 15.4.8.2. Phase of Drug Development Portfolio; 15.4.8.3. Financial Overview; 15.4.8.4. Strategic Overview; 15.4.8.5. SWOT Analysis; 15.4.9. iGATE Corporation; 15.4.9.1. Company Overview (HQ, Business Segments, Employee Strength); 15.4.9.2. Phase of Drug Development Portfolio; 15.4.9.3. Financial Overview; 15.4.9.4. Strategic Overview; 15.4.9.5. SWOT Analysis; 15.4.10. iMEDGlobal Corporation; 15.4.10.1. Company Overview (HQ, Business Segments, Employee Strength); 15.4.10.2. Phase of Drug Development Portfolio; 15.4.10.3. Strategic Overview; 15.4.10.4. SWOT Analysis; 15.4.11. Syneos Health; 15.4.11.1. Company Overview (HQ, Business Segments, Employee Strength); 15.4.11.2. Phase of Drug Development Portfolio; 15.4.11.3. Financial Overview; 15.4.11.4. Strategic Overview; 15.4.11.5. SWOT Analysis; 15.4.12. Novartis AG; 15.4.12.1. Company Overview (HQ, Business Segments, Employee Strength); 15.4.12.2. Phase of Drug Development Portfolio; 15.4.12.3. Financial Overview; 15.4.12.4. Strategic Overview; 15.4.12.5. SWOT Analysis; 15.4.13. PAREXEL International Corporation; 15.4.13.1. Company Overview (HQ, Business Segments, Employee Strength); 15.4.13.2. Phase of Drug Development Portfolio; 15.4.13.3. Financial Overview; 15.4.13.4. Strategic Overview; 15.4.13.5. SWOT Analysis; 15.4.14. Pfizer, Inc.; 15.4.14.1. Company Overview (HQ, Business Segments, Employee Strength); 15.4.14.2. Phase of Drug Development Portfolio; 15.4.14.3. Financial Overview; 15.4.14.4. Strategic Overview; 15.4.14.5. SWOT Analysis; 15.4.15. Pharmaceutical Phase of Drug Development, LLC. (PPD); 15.4.15.1. Company Overview (HQ, Business Segments, Employee Strength); 15.4.15.2. Phase of Drug Development Portfolio; 15.4.15.3. Financial Overview; 15.4.15.4. Strategic Overview; 15.4.15.5. SWOT Analysis; 15.4.16. IQVIA; 15.4.16.1. Company Overview (HQ, Business Segments, Employee Strength); 15.4.16.2. Phase of Drug Development Portfolio; 15.4.16.3. Financial Overview; 15.4.16.4. Strategic Overview; 15.4.16.5. SWOT Analysis; 15.4.17. Sanofi; 15.4.17.1. Company Overview (HQ, Business Segments, Employee Strength); 15.4.17.2. Phase of Drug Development Portfolio; 15.4.17.3. Financial Overview; 15.4.17.4. Strategic Overview; 15.4.17.5. SWOT Analysis; 15.4.18. Synowledge LLC; 15.4.18.1. Company Overview (HQ, Business Segments, Employee Strength); 15.4.18.2. Phase of Drug Development Portfolio; 15.4.18.3. Strategic Overview; 15.4.18.4. SWOT Analysis; 15.4.19. Wipro Limited; 15.4.19.1. Company Overview (HQ, Business Segments, Employee Strength); 15.4.19.2. Phase of Drug Development Portfolio; 15.4.19.3. Financial Overview; 15.4.19.4. Strategic Overview; 15.4.19.5. SWOT Analysis